These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 22153646

  • 1. Can genetic factors predict response to antivascular endothelial growth factor therapy in age-related macular degeneration?
    Micieli JA.
    Can J Ophthalmol; 2011 Dec; 46(6):549-51. PubMed ID: 22153646
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacogenetics of the treatment response of age-related macular degeneration with ranibizumab and bevacizumab.
    Kanoff J, Miller J.
    Semin Ophthalmol; 2013 Dec; 28(5-6):355-60. PubMed ID: 24010796
    [Abstract] [Full Text] [Related]

  • 3. New treatments for age-related macular degeneration.
    Avery RL.
    Lancet; 2007 Oct 27; 370(9597):1479-80; author reply 1480. PubMed ID: 17964341
    [No Abstract] [Full Text] [Related]

  • 4. Response to Replacing ranibizumab with bevacizumab on the Pharmaceutical Benefits Scheme: where does the current evidence leave us?
    O'Shea JG.
    Clin Exp Optom; 2012 Sep 27; 95(5):541-3. PubMed ID: 22672003
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
    Kaiser PK.
    Am J Ophthalmol; 2006 Oct 27; 142(4):660-8. PubMed ID: 17011860
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Age-related visual loss].
    Neubauer AS, Kernt M.
    MMW Fortschr Med; 2013 Feb 07; 155(2):36-7. PubMed ID: 23573743
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Bevacizumab in ophthalmology: the controversy moves forward.
    Gillies MC.
    Clin Exp Ophthalmol; 2010 May 07; 38(4):333-4. PubMed ID: 20642588
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Association of the polymorphism Y402H in the CFH gene with response to anti-VEGF treatment in age-related macular degeneration: a systematic review and meta-analysis.
    Hong N, Shen Y, Yu CY, Wang SQ, Tong JP.
    Acta Ophthalmol; 2016 Jun 07; 94(4):334-45. PubMed ID: 27151934
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Debate on the various anti-vascular endothelial growth factor drugs.
    Khalili MR, Hosseini H.
    Indian J Ophthalmol; 2008 Jun 07; 56(3):255-6; author reply 256. PubMed ID: 18417837
    [No Abstract] [Full Text] [Related]

  • 19. Bevacizumab: not as good with more adverse reactions?
    Beaumont P.
    Clin Exp Ophthalmol; 2011 Aug 07; 39(6):588-90. PubMed ID: 21631687
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.